Screening Platform for Cancer Eligibility
Trial Summary
What is the purpose of this trial?
The study objective is to determine the biomarker status of a participant's tumor tissue and use that status to determine eligibility for a linked Roche clinical trial.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
What data supports the effectiveness of the Screening platform treatment for cancer?
Is the cancer screening platform generally safe for humans?
How is this cancer screening treatment different from other treatments?
This treatment is unique because it focuses on screening healthy individuals to detect cancer early, which can lead to better outcomes by identifying the disease before symptoms appear. Unlike other treatments that target existing cancer, this approach aims to prevent cancer progression by catching it early through organized and systematic screening programs.110111213
Research Team
Clinical Trials
Principal Investigator
Hoffmann-La Roche
Eligibility Criteria
This trial is for people with solid tumors who have a tumor sample available and are considered candidates for an upcoming clinical trial. They must be willing to participate in the new trial. People with significant liver or heart disease, other recent cancers (except certain low-risk types), or past organ transplants cannot join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Biomarker Assessment
Participants' tumor tissue is assessed to determine biomarker status for eligibility in a linked Roche clinical trial
Follow-up
Participants are monitored for safety and effectiveness after biomarker assessment
Treatment Details
Interventions
- Screening platform
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hoffmann-La Roche
Lead Sponsor
Dr. Levi Garraway
Hoffmann-La Roche
Chief Medical Officer since 2019
MD from the University of Basel
Dr. Thomas Schinecker
Hoffmann-La Roche
Chief Executive Officer since 2023
PhD in Molecular Biology from New York University